Stay updated with breaking news from Marial Maccecchini. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MALVERN, Pa., April 02, 2024 -- Annovis Bio, Inc. , a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates...
MALVERN, Pa., Jan. 30, 2024 -- Annovis Bio, Inc. , a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application...
Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer’s Disease is sufficiently powered to continue as planned without any...
Phase 2/3 AD Study continues to make steady progress in patient recruitment Company to hold R&D webcast on Thursday, April 20th to review ongoing clinical programs in Alzheimer's disease and... | April 19, 2023
/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, has...